Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

6 May 2015

journal article
research article
Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine

Vol. 7 (286) , 286re5
https://doi.org/10.1126/scitranslmed.aaa2373

Abstract

Vaccination with the recombinant viral vectors chimpanzee adenovirus 63 followed by modified vaccinia Ankara both encoding the malaria sequence ME-TRAP conferred 67% protection against infection with Plasmodium falciparum in Kenyan adults.

Keywords

Funding Information

Wellcome Trust (097940/Z/11/Z, B9RTIR0)
Wellcome Trust Centre for Human Genetics (075491/Z/04, 090532/Z/09/Z)
Senior Wellcome Trust Fellowship (79082)
U.K. Medical Research Council (MRC)
U.K. Department for International Development (DFID)
European and Developing Countries Clinical Trials Partnership (IP.2008.31100.001)

This publication has 31 references indexed in Scilit:

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data
The Lancet Infectious Diseases, 2013
Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection
The Journal of Infectious Diseases, 2013
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
New England Journal of Medicine, 2012
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
The Journal of Infectious Diseases, 2012
Wind direction and proximity to larval sites determines malaria risk in Kilifi District in Kenya
Nature Communications, 2012
Vaccines against malaria
Philosophical Transactions Of The Royal Society B-Biological Sciences, 2011
Substantially Reduced Pre-patent Parasite Multiplication Rates Are Associated With Naturally Acquired Immunity to Plasmodium falciparum
The Journal of Infectious Diseases, 2011
Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
The Journal of Infectious Diseases, 2009
Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge
Infection and Immunity, 2007
A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite Challenge
Infection and Immunity, 2006